Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Long-acting insulin is safer, more effective for patients with Type 1 diabetes

01.10.2014

Long-acting insulin is safer and more effective than intermediate-acting insulin for patients with Type 1 diabetes, according to new research published in the BMJ.

Researchers looked at once-daily and twice-daily doses of both long- and intermediate-acting insulin, ranking their effectiveness, safety and cost-effectiveness.


"In patients with Type 1 diabetes, we found that long-acting insulin is superior to intermediate-acting insulin when it came to controlling blood sugar, preventing weight gain and treating severe hypoglycemia," said Dr. Andrea Tricco, the lead author of the paper and a scientist in the Li Ka Shing Knowledge Institute of St. Michael's Hospital.

Credit: Antonia Giroux Photography

"In patients with Type 1 diabetes, we found that long-acting insulin is superior to intermediate-acting insulin when it came to controlling blood sugar, preventing weight gain and treating severe hypoglycemia," said Dr. Andrea Tricco, the lead author of the paper and a scientist in the Li Ka Shing Knowledge Institute of St. Michael's Hospital.

Using data from 39 studies, Dr. Tricco and her colleagues compared two long-acting forms of insulin – glargine and detemir – against intermediate-acting forms, such as such as Neutral Protamine Hagedorn.

Long-acting insulin takes about one hour after ingesting to begin lowering blood sugar and lasts up to 26 hours. Intermediate-acting insulin takes between one and three hours to begin lowering blood sugar and can last up to 16 hours.

Compared to intermediate-acting NPH, long-acting insulin significantly improved Hemoglobin A1C levels, a measure of effective blood sugar control over time.

"Those taking intermediate-acting insulin were more likely to gain weight," said Dr. Tricco, who has a PhD in population health and is also an assistant professor in the University of Toronto's Dalla Lana School of Public Health. "They gained an average of four to six pounds more than the participants who took most long-acting insulin doses."

Severe hypoglycemia, when someone has extremely low blood sugar, is a medical emergency where the individual is unable to treat themselves. When someone is severely hypoglycemic, they need someone else to provide them with sugar quickly through food or via intravenous fluids.

The researchers found that people with Type 1 diabetes were 38 per cent less likely to experience severe hypoglycemia, on average.

Dr. Tricco also looked at the cost-effectiveness between the two types of insulin.

Of the 32 studies included in the review, there were 22 analyses evaluating the economic benefits of long- and intermediate-acting insulin. Seventy-seven per cent of those economic analyses found that long-acting insulin was more expensive but also more effective than intermediate-acting insulin. Twenty-three per cent found long-acting insulin more cost-effective.

"With this information, patients and their doctors should tailor their choice of insulin according to preference, cost and accessibility," said Dr. Tricco.

###

This research was funded by the Drug Safety and Effectiveness Network of Canadian Institutes of Health Research.

About St. Michael's Hospital

St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in 27 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, care of the homeless and global health are among the hospital's recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Centre, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

Media contacts
For more information, or to arrange an interview, please contact:
Geoff Koehler
Adviser, Media Relations
St. Michael's Hospital
416-864-6060 ext. 6537
koehlerg@smh.ca

Geoff Koehler | Eurek Alert!
Further information:
http://www.stmichaelshospital.com/

Further reports about: Health analyses blood sugar blood sugar control hypoglycemia types of insulin

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Morbid Obesity: Gastric Bypass and Sleeve Gastrectomy Are Comparable

17.01.2018 | Health and Medicine

Researchers identify new way to unmask melanoma cells to the immune system

17.01.2018 | Health and Medicine

Genetic discovery may help better identify children at risk for type 1 diabetes

17.01.2018 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>